Recently, Trinomab Biotechnology Co., Ltd. (Trinomab Biotech) has made new progress for new product development.The domestically developed human monoclonal antibody against tetanus toxin TNM002 has been officially approved by Human Research Ethics Committee (HREC) and Therapeutic Goods Administration (TGA) in Australia for the Phase I clinical trial. It is the world’s first human monoclonal antibody against tetanus toxin started human clinical trail.
Tetanus is an acute infectious disease caused by caused by the tetanus bacterium Clostridium tetani, which enters the body through skin wound or tissue damage such as trauma, burns, rabies II/III exposure, traffic accidents etc. Tetanus toxin causes central nervous system dysfunction. Symptoms occur anytime from a few days to several weeks after tetanus bacteria enter human body through a wound. Case fatality rate of severe tetanus is as high as 30-50% according to a research. And the rate is close to 100% in some low-income and middle-income countries .
TNM002 is a natural human monoclonal antibody developed by Trinomab’s HitMab technology platform with self-dependence intellectual property. Preclinical study shows that TNM002 is with strong specificity, good safety, and high neutralization ability with tetanus toxin. As a new generation of human monoclonal antibody drugs by gene recombination technology, TNM002 is have potential replace the traditional Equine tetanus immunoglobulin (antitoxin TAT) and Human tetanus immunoglobulin (human tetanus immunoglobulin HTIG), bringing greater benefits to patients.
About Trinomab
Trinomab Biotechnology Co., Ltd (Trinomab) is a startup pharmaceutical company focused on the research and development of new, fully native human antibody drugs to fight infectious, autoimmune, and other diseases as well as malignant tumors.
Updated 2021.3.21
Latest report shows that Trinomab receives IND approval from the FDA for TNM002 Monoclonal antibody. This is another successful clinical application after the approval of HREC/TGA in November 2020.
